COVID19 vaccination in adults with sickle cell disease is not associated with increases in rates of pain crisis.
COVID19 vaccination in adults with sickle cell disease is not associated with increases in rates of pain crisis.
复制标题
DOI：
10.1080/16078454.2022.2085072
复制
发表时间：
2022-12
期刊：
影响因子：
1.9
通讯作者：
Curtis, Susanna
中科院分区：
文献类型：
--
作者：
Friedman, Elana;Minniti, Caterina;Campbell, Sean;Curtis, Susanna
患有镰状细胞病（SCD）的人更容易在COVID-19感染后住院，肺炎和疼痛。然而，鉴于SCD中炎症反应与血管闭塞性危象之间的关联以及ChAdOx 1 nCov-195-7/阿斯利康疫苗接种后血管闭塞性危象的病例报告，人们担心在SCD患者中接种COVID-19疫苗可能会引发血管闭塞性危象。为了解决这一关键的知识缺口，我们试图检查Montefiore镰状细胞中心成人患者中血管闭塞危象的急性护理使用情况以及COVID-19疫苗接种后副作用的频率和严重程度。作为常规护理的一部分，患者被询问是否接受了COVID-19疫苗接种，并注意到任何副作用。对电子病历进行了审查，包括疫苗类型、接种日期、接种后7天内血管闭塞性危象的发作情况以及注意到的副作用。计算2019年每周平均医院利用率的风险作为基线。我们发现，不到十分之一的患者在接种疫苗后七天内到医院就诊，医院利用的风险与2019年一周内的平均风险相似。在报告副作用的患者中，1例报告了可能的感音神经性听力损失病例，否则未报告其他罕见副作用，包括血栓形成或死亡。
People with sickle cell disease (SCD) are more vulnerable to hospitalization, pneumonia, and pain following COVID-19 infection. However, given the association between the inflammatory response and vaso-occlusive crises in SCD and a case report of vaso-occlusive crises following administration of the ChAdOx1 nCov-195-7/AstraZeneca vaccine, there is concern that the administration of COVID-19 vaccines in people with SCD might provoke a vaso-occlusive crisis. To address this critical gap in knowledge, we sought to examine acute care usage for vaso-occlusive crisis and frequency and severity of side effects following COVID-19 vaccination among patients at the Montefiore Sickle Cell Center for Adults. As part of regular care, patients were asked if they had received COVID-19 vaccination and any side effects were noted. Electronic medical records were reviewed for the type of vaccine, dates received, episodes of vaso-occlusive crises within seven days of a dose, and side effects noted. The risk of average hospital utilization per week in 2019 was calculated as a baseline. We found that fewer than 1 in 10 patients presented to the hospital within seven days of vaccination and that the risk of hospital utilization was similar to the average risk in a week in 2019. Of patients who reported side effects, one reported a possible case of sensorineural hearing loss otherwise no other rare side effects, including thrombosis or death, were reported.
登录
查看更多内容
DOI：
10.1016/j.ijid.2021.10.025
发表时间：
2021-12
期刊：
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
影响因子：
--
作者：
Jeong J;Choi HS
通讯作者：
Choi HS
DOI：
10.4084/mjhid.2021.059
发表时间：
2021
影响因子：
3.2
作者：
Alkindi S;Elsadek RA;Pathare AV
通讯作者：
Pathare AV
DOI：
10.7759/cureus.21026
发表时间：
2022-01
期刊：
Cureus
影响因子：
--
作者：
Jan H;Waheeb A;AlAhwal H;Almohammadi A;Al-Marzouki A;Barefah A;Bahashawan S;Radhwi O
通讯作者：
Radhwi O
与其他黑人个体相比，患有镰状细胞病/性状的个体中的 COVID-19。
影响因子：
7.5
作者：
Singh A;Brandow AM;Panepinto JA
通讯作者：
Panepinto JA
影响因子：
20.3
作者：
Merkeley H;McGuire M;Ding L;McCartney H;Amid A;Strahlendorf C;Sandhu N;Vergidis D;O'Donnell M
通讯作者：
O'Donnell M